A foundation of treatment in HER2+ cancer1-3
20 years of experience since first approval4
Access and Choice
Find out more about Genentech’s commitment to supporting patient access and physician choice.
Learn more about the range of patient support services Genentech offers for your patient’s treatment.
A Subcutaneous Option
Learn about Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk), a subcutaneous trastuzumab treatment option for eligible HER2+ patients.5